Drugs / EPI-321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06907875 | May 2025 → Jul 2027 expected | facioscapulohumeral muscular dystrophy | Epicrispr Biotechnologies, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPI-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06907875 ↗ |
| Action | Inhibit | “repress the expression of toxic DUX4 protein” NCT06907875 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated viral vector, serotype rh74 (AAVrh74)” NCT06907875 ↗ |
| Route | Intravenous | “following a single intravenous (IV) dose” NCT06907875 ↗ |
| Target | DUX4 | “repress the expression of toxic DUX4 protein” NCT06907875 ↗ |